Ada Girnita

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ONCOGENE. 2022;41(4):600-611

IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma

Song D; Cismas S; Crudden C; Trocme E; Worrall C; Suleymanova N; Lin T; Zheng H; Seregard S; Girnita A; Girnita L
Article: JOURNAL OF DRUGS IN DERMATOLOGY. 2021;20(12):ss4-s14

Skincare for Cancer Patients in Scandinavia

Girnita A; Lorentzen HF; Kauppi S; Lynde CW; Sauder MB; Schmidt H; Andriessen A; Stensvold A
Article: CANCER RESEARCH. 2021;81(2):501-514

Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth

Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting

Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: ACTA DERMATO-VENEREOLOGICA. 2020;100(17):adv00282-0

Ten-year Follow-up Study of Grenz Ray Treatment for Lentigo Maligna and Early Lentigo Maligna Melanoma

Drakensjo IRT; Rosen E; Frohm Nilsson M; Girnita A
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2019;33:13-27

Prevalence and determinants of sunbed use in thirty European countries: data from the Euromelanoma skin cancer prevention campaign

Suppa M; Gandini S; Njimi H; Bulliard JL; Correia O; Duarte AF; Peris K; Stratigos AJ; Nagore E; Longo MI; Bylaite-Bucinskiene M; Karls R; Helppikangas H; del Marmol V; Baltas E; Bogomolets O; Girnita A; Hafner J; Hercogova J; Konno P; Lorentzen HF; Maselis T; Medenica L; Mekokishvili L; Murphy M; Nedelciuc B; Nicolescu AC
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2019;33:76-88

Association of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaign

Suppa M; Gandini S; Njimi H; Bulliard JL; Correia O; Duarte AF; Peris K; Stratigos AJ; Nagore E; Longo MI; Bylaite-Bucinskiene M; Karls R; Helppikangas H; del Marmol V; Baltas E; Bogomolets O; Girnita A; Hafner J; Hercogova J; Konno P; Lorentzen HF; Maselis T; Medenica L; Mekokishvili L; Murphy M; Nedelciuc B; Nicolescu AC; Olah J; Onsun N; Pallouras A; Placek W; Potekaev N; Reusch M; Roscher I; Rucigaj TP; Scerri SL; Situm MM; Zafirovik Z
Article: ONCOTARGET. 2018;9(74):33871-33883

IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line.

Furuta H; Yoshihara H; Fukushima T; Yoneyama Y; Ito A; Worrall C; Girnita A; Girnita L; Yoshida M; Asano T; Komada M; Kataoka N; Chida K; Hakuno F; Takahashi S-I
Article: PLOS ONE. 2018;13(10):e0205517

Differences in cutaneous melanoma treatment and patient satisfaction

Wikstrom JD; Lundeberg L; Frohm-Nilsson M; Girnita A
Article: ONCOGENE. 2017;36(41):5734-5744

Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes

Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
Article: ONCOTARGET. 2017;8(47):82256-82267

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation

Suleymanova N; Crudden C; Worrall C; Dricu A; Girnita A; Girnita L
Article: ONCOGENE. 2017;36(23):3274-3286

Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma

Worrall C; Suleymanova N; Crudden C; Drakensjo IT; Candrea E; Nedelcu D; Takahashi S-I; Girnita L; Girnita A
Article: LAKARTIDNINGEN. 2015;112:C6RC

[Treated patients in survey: High satisfaction with botulinum toxin in palmar hyperhidrosis].

Deebaj R; Emtestam L; Lundeberg L; Brandin Samuelsson K; Girnita A
Article: PEDIATRIC ENDOCRINOLOGY REVIEWS PER. 2013;10(4):473-484

Novel Mechanisms of Regulation of IGF-1R Action: Functional and Therapeutic Implications

Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(50):20620-20625

β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma

Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(18):7055-7060

Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor

Zheng H; Worrall C; Shen H; Issad T; Seregard S; Girnita A; Girnita L
Article: NEURO-ONCOLOGY. 2010;12(1):19-27

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma

Yin S; Girnita A; Stromberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nister M; Larsson O; Ekstrom TJ; Girnita L
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:35-41

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:26-34

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2337-2342

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2008;368(3):793-800

Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth

Toernkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Article: ONCOGENE. 2008;27(11):1629-1638

Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1

Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Article: MOLECULAR PHARMACOLOGY. 2008;73(3):930-939

Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin

Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(15):11329-11338

β-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression

Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Vasilcanu D; Girnita A; Lefkowitz RJ; Larsson O
Article: BRITISH JOURNAL OF CANCER. 2007;96 Suppl:R2-R6

Role of insulin-like growth factor 1 receptor signalling in cancer.

Larsson O; Girnita A; Girnita L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;347(4):1059-1066

IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-)

Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
Article: ONCOGENE. 2006;25(22):3186-3195

The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection

Vasilcanu D; Weng W-H; Girnita A; Lui W-O; Vasilcanu R; Axelson M; Larsson O; Larsson C; Girnita L
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1383-1391

The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells

Girnita A; All-Ericsson C; Economou MA; Åström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4674-4680

Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells:: A novel therapeutic approach

Ulfarsson E; Karström A; Yin SC; Girnita A; Vasilcanu D; Thoren M; Kratz G; Hillman J; Axelson M; Larsson O; Girnita L
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(26):24412-24419

β-arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase

Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
Article: ONCOGENE. 2004;23(47):7854-7862

The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway

Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Article: CANCER RESEARCH. 2004;64(1):236-242

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth

Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(14):8247-8252

Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor

Girnita L; Girnita A; Larsson O
Article: CANCER RESEARCH. 2000;60(18):5278-5283

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact

Girnita L; Girnita A; Brodin B; Xie YT; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Article: ONCOGENE. 2000;19(37):4298-4301

A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells

Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2000;165(1-2):131-137

Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway

Kanter-Lewensohn L; Girnita L; Girnita A; Dricu A; Olsson G; Leech L; Nilsson G; Hilding A; Wejde J; Brismar K; Larsson O
Visa fler

Alla övriga publikationer

Review: LAKARTIDNINGEN. 2021;118:21114

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].

Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Corrigendum: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(6):1407

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting (vol 35, pg 105, 2021)

Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma

Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Review: CELLS. 2019;8(10):E1223-1223

Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey

Crudden C; Song D; Cismas S; Trocme E; Pasca S; Calin GA; Girnita A; Girnita L
Review: CHROMATIN AND GENOMIC INSTABILITY IN CANCER. 2018;339:1-40

Blurring Boundaries: Receptor Tyrosine Kinases as functional G Protein-Coupled Receptors

Crudden C; Shibano T; Song D; Suleymanova N; Girnita A; Girnita L
Review: FRONTIERS IN ONCOLOGY. 2018;8:202

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment

Helgadottir H; Drakensjo IRT; Girnita A
Review: PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY. 2016;141:277-311

When Phosphorylation Encounters Ubiquitination: A Balanced Perspective on IGF-1R Signaling

Girnita L; Takahashi S-I; Crudden C; Fukushima T; Worrall C; Furuta H; Yoshihara H; Hakuno F; Girnita A
Review: GROWTH HORMONE & IGF RESEARCH. 2015;25(1):2-12

The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?

Crudden C; Ilic M; Suleyrnanova N; Worrall C; Girnita A; Girnita L
Review: FRONTIERS IN ENDOCRINOLOGY. 2015;6:64

Targeting the IGF-1R: the tale of the tortoise and the hare

Crudden C; Girnita A; Girnita L
Review: CELLULAR AND MOLECULAR LIFE SCIENCES. 2014;71(13):2403-2427

Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation

Girnita L; Worrall C; Takahashi S-I; Seregard S; Girnita A
Review: LAKARTIDNINGEN. 2013;110(8):410-412

[Synchronous multiple primary melanoma are often missed. Increased attention to the patient's entire skin is required for early diagnosis].

Lapins J; Emtestam L; Hedblad M-A; Girnita A; Lindelöf B; Ljung A; Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(3):16

β-arrestin-dependent signaling by IGF-1R regulates the Ras induced transformation of mammalian cells

Zheng H; Natalishvili N; Mateoiu C; Girnita A; Girnita L
Review: BRITISH JOURNAL OF CANCER. 2005;92(12):2097-2101

Role of insulin-like growth factor 1 receptor signalling in cancer

Larsson O; Girnita A; Girnita L
Meeting abstract: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2004;50(3):P117

Possible use of flavonoids as cell growth inhibitors in malignant melanoma

Girnita A; Girnita L; Axelson M; Larsson O

Anställningar

Forskare, Klin, Onkologi-Patologi, Karolinska Institutet, 2012-2025

Examina och utbildning

Docent, Dermatologi och venereologi, Karolinska Institutet, 2021
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2004

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI